New cancer drug enters first human safety tests
NCT ID NCT05290597
Summary
This is an early-stage study to find a safe dose of a new experimental drug called IBI363. It is for adults with advanced solid tumors or lymphomas that have not responded to other available treatments. The main goal is to check the drug's safety and side effects in a small group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES OR LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Wollongong
Sydney, New South Wales, 2500, Australia
-
Sydney, New South Wales, 2109, Australia
-
Sydney Southwest Private Hospital
Sydney, New South Wales, 2170, Australia
-
Westmead Hospital
Sydney, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.